MRNA * Stock Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1,760.00 |
52 Week High | US$2,600.44 |
52 Week Low | US$1,200.00 |
Beta | 1.59 |
1 Month Change | 0% |
3 Month Change | 2.92% |
1 Year Change | -30.98% |
3 Year Change | -47.48% |
5 Year Change | 243.75% |
Change since IPO | 243.75% |
Recent News & Updates
Recent updates
Shareholder Returns
MRNA * | MX Biotechs | MX Market | |
---|---|---|---|
7D | -0.3% | 0% | 0% |
1Y | -31.0% | 0% | 0% |
Return vs Industry: MRNA * underperformed the MX Biotechs industry which returned -8% over the past year.
Return vs Market: MRNA * underperformed the MX Market which returned 0.6% over the past year.
Price Volatility
MRNA * volatility | |
---|---|
MRNA * Average Weekly Movement | 9.3% |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in MX Market | 0% |
10% least volatile stocks in MX Market | 0% |
Stable Share Price: MRNA * has not had significant price volatility in the past 3 months.
Volatility Over Time: MRNA *'s weekly volatility (9%) has been stable over the past year, but is still higher than 75% of MX stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
MRNA * fundamental statistics | |
---|---|
Market cap | Mex$666.18b |
Earnings (TTM) | -Mex$80.41b |
Revenue (TTM) | Mex$116.81b |
5.7x
P/S Ratio-8.3x
P/E RatioIs MRNA * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MRNA * income statement (TTM) | |
---|---|
Revenue | US$6.85b |
Cost of Revenue | US$9.54b |
Gross Profit | -US$2.69b |
Other Expenses | US$2.02b |
Earnings | -US$4.71b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | -12.31 |
Gross Margin | -39.28% |
Net Profit Margin | -68.84% |
Debt/Equity Ratio | 0% |
How did MRNA * perform over the long term?
See historical performance and comparison